

## Brilliant Violet 605™ anti-mouse/human CD45R/B220 Antibody

<b>Catalog# / Size</b>	103243 / 125 µL 103244 / 50 µg
<b>Clone</b>	RA3-6B2
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	B220
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL- <i>Fas<sup>lpr</sup></i> and MRL- <i>Fas<sup>gld</sup></i> mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

### Product Details

<b>Verified Reactivity</b>	Mouse, Human
<b>Reported Reactivity</b>	Cat
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Abelson murine leukemia virus-induced pre-B tumor cells
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
<b>Concentration</b>	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.  Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. <b>Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.</b> Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

[Learn more about Brilliant Violet™.](#)

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign

equivalents.

**Excitation Laser**

Violet Laser (405 nm)

**Application Notes**

Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation<sup>1</sup>, *in vitro* and *in vivo* modulation of B cell responses<sup>2-4</sup>, immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections<sup>5,6</sup>, and spatial biology (IBEX)<sup>14,15</sup>.

**Application References**

(PubMed link indicates BioLegend citation)

1. Coffman RL. 1982. *Immunol. Rev.* 69:5. (IP)
2. George A, *et al.* 1994. *J. Immunol.* 152:1014. (Activ)
3. Asensi V, *et al.* 1989. *Immunology* 68:204. (Activ)
4. Domiati-Saad R, *et al.* 1993. *J. Immunol.* 151:5936. (Activ)
5. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Monteith CE, *et al.* 1996. *Can. J. Vet. Res.* 60:193. (IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Chang C L-T, *et al.* 2007. *J. Immunol.* 178:6984.
9. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
10. Lang GL, *et al.* 2008. *Blood* 111:2158. [PubMed](#)
11. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
12. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
13. Murakami R, *et al.* 2013. *PLoS One.* 8:73270. [PubMed](#)
14. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
15. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

**Product Citations**

1. Yu-Han Chang *et al.* 2017. *Immunity.* 47(5):943-958 . [PubMed](#)
2. Wang KC, *et al.* 2018. *Immunohorizons.* 2:407. [PubMed](#)
3. McNamara HA, *et al.* 2020. *Cell Host Microbe.* 572:28. [PubMed](#)
4. Kim EH, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
5. Chen S, *et al.* 2022. *Cancer Discov. .* [PubMed](#)
6. Farsakoglu Y *et al.* 2019. *Cell reports.* 26(9):2307-2315 . [PubMed](#)
7. Sangesland M, *et al.* 2020. *Immunity.* 51(4):735-749. [PubMed](#)
8. Chen J, *et al.* 2022. *Nat Commun.* 13:6759. [PubMed](#)
9. Wang H, *et al.* 2022. *Curr Protoc.* 2:e446. [PubMed](#)
10. Treger RS, *et al.* 2020. *Immunity.* 50(2):334-347.e9.. [PubMed](#)
11. Best SA, *et al.* 2018. *Cell Metab.* 27:935. [PubMed](#)
12. Kim SP, *et al.* 2021. *Cell Reports.* 36(9):109626. [PubMed](#)
13. Lopez DA, *et al.* 2022. *Cell Rep.* 41:111677. [PubMed](#)
14. Stump CT, *et al.* 2021. *Open Biol.* 11:210245. [PubMed](#)
15. Rios D, *et al.* 2015. *Mucosal Immunol.* 101038/mi. [PubMed](#)
16. Viant C, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)
17. Poon E, *et al.* 2017. *J Immunother Cancer.* 10.1186/s40425-017-0268-8. [PubMed](#)
18. Bourque J, *et al.* 2021. *Heliyon.* 7:e08311. [PubMed](#)
19. Mittal A, *et al.* 2021. *Sci Rep.* 11:10731. [PubMed](#)
20. Zhang H, *et al.* 2019. *Mol Cell.* 76:110. [PubMed](#)
21. Jacque E, *et al.* 2015. *J Exp Med.* 212:883. [PubMed](#)
22. Soni C, *et al.* 2020. *Immunity.* 52(6):1022-1038.e7. [PubMed](#)
23. Frost JN, *et al.* 2021. *Med (N Y).* 2:164. [PubMed](#)
24. Andersen L, *et al.* 2020. *Cell Reports.* 29(13):4447-4459.e6.. [PubMed](#)
25. Biram A, *et al.* 2020. *Bio Protoc.* e3562:10. [PubMed](#)
26. Chatterjee D, *et al.* 2021. *Cell Reports.* 35(2):108996. [PubMed](#)
27. Cunha LD *et al.* 2018. *Cell.* 175(2):429-441 . [PubMed](#)
28. Zhou X, *et al.* 2021. *Cell Reports.* 34(1):108601. [PubMed](#)
29. Clancy-Thompson E, *et al.* 2019. *EMBO J.* 38:e101260. [PubMed](#)
30. Xu JL, *et al.* 2022. *Front Pharmacol.* 13:911663. [PubMed](#)
31. Ghezraoui H, *et al.* 2018. *Nature.* 560:122. [PubMed](#)
32. Coley WD *et al.* 2018. *F1000Research.* 2018 Mar 14 [revised 2018 Jan 1] 0.5125. [PubMed](#)
33. Baglaenko Y, *et al.* 2016. *PLoS One.* 11: 0150515. [PubMed](#)
34. Di Pilato M, *et al.* 2021. *Cell.* 184(17):4512-4530.e22. [PubMed](#)
35. Viant C, *et al.* 2020. *Cell.* 183:1298. [PubMed](#)
36. Schuh E, *et al.* 2017. *J Immunol.* 198:3081. [PubMed](#)
37. Heyde A, *et al.* 2021. *Cell.* 184(5):1348-1361.e22. [PubMed](#)
38. Viant C, *et al.* 2021. *STAR Protocols.* 2(2):100389. [PubMed](#)
39. Finkin S *et al.* 2019. *Immunity.* 51(2):324-336 . [PubMed](#)

**RRID**

AB\_11203907 (BioLegend Cat. No. 103243)  
AB\_2563312 (BioLegend Cat. No. 103244)

**Antigen Details**

**Structure**

Protein tyrosine phosphatase (PTP) family, 180-240 kD

<b>Distribution</b>	B cells, T cell subset, NK cell subset
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4
<b>Cell Type</b>	B cells, NK cells, T cells
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press.</li> <li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li> <li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li> <li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li> </ol>
<b>Gene ID</b>	<a href="#">19264</a> <a href="#">5788</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Alexa Fluor® 594 anti-mouse/human CD45R/B220, APC anti-mouse/human CD45R/B220, Biotin anti-mouse/human CD45R/B220, FITC anti-mouse/human CD45R/B220, PE anti-mouse/human CD45R/B220, PE/Cyanine5 anti-mouse/human CD45R/B220, Purified anti-mouse/human CD45R/B220, PE/Cyanine7 anti-mouse/human CD45R/B220, APC/Cyanine7 anti-mouse/human CD45R/B220, Alexa Fluor® 488 anti-mouse/human CD45R/B220, Alexa Fluor® 647 anti-mouse/human CD45R/B220, Pacific Blue™ anti-mouse/human CD45R/B220, Alexa Fluor® 700 anti-mouse/human CD45R/B220, PerCP anti-mouse/human CD45R/B220, PerCP/Cyanine5.5 anti-mouse/human CD45R/B220, Brilliant Violet 421™ anti-mouse/human CD45R/B220, Brilliant Violet 570™ anti-mouse/human CD45R/B220, Brilliant Violet 650™ anti-mouse/human CD45R/B220, Brilliant Violet 605™ anti-mouse/human CD45R/B220, Brilliant Violet 785™ anti-mouse/human CD45R/B220, Brilliant Violet 510™ anti-mouse/human CD45R/B220, Purified anti-mouse/human CD45R/B220 (Maxpar® Ready), Brilliant Violet 711™ anti-mouse/human CD45R/B220, PE/Dazzle™ 594 anti-mouse/human CD45R/B220, APC/Fire™ 750 anti-mouse/human CD45R/B220, Brilliant Violet 750™ anti-mouse/human CD45R/B220, TotalSeq™-A0103 anti-mouse/human CD45R/B220, Spark Blue™ 550 anti-mouse/human CD45R/B220, Spark NIR™ 685 anti-mouse/human CD45R/B220, TotalSeq™-B0103 anti-mouse/human CD45R/B220, Ultra-LEAF™ Purified anti-mouse/human CD45R/B220, TotalSeq™-C0103 anti-mouse/human CD45R/B220, PE/Fire™ 640 anti-mouse/human CD45R/B220, APC/Fire™ 810 anti-mouse/human CD45R/B220, PE/Fire™ 700 anti-mouse/human CD45R/B220, Spark Violet™ 538 anti-mouse/human CD45R/B220, Spark YG™ 581 anti-mouse/human CD45R/B220, Spark YG™ 570 anti-mouse/human CD45R/B220, PE/Fire™ 810 anti-mouse/human CD45R/B220, Spark Blue™ 574 anti-mouse/human CD45R/B220 Antibody, Spark Violet™ 423 anti-mouse/human CD45R/B220 Antibody, Spark Red™ 718 anti-mouse/human CD45R/B220

## Product Data



C57BL/6 mouse splenocytes were stained with CD45R/B220 (clone RA3-6B2) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic,

therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587